Journals / Glokom Katarakt / 2010 / Cilt: 5 - Sayı: 2

The impact of topical latanoprost, bimatoprost and travoprost on central corneal thickness

Topikal latanoprost, bimatoprost ve travoprostun santral kornea kalınlığına etkileri

Pages
97–101
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

It may be important to obtain pachymetry measurements at each visit in the early period of primary open angle glaucoma treatment.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To investigate the possible impact of latanoprost, bimatoprost and travoprost on central corneal thickness (CCT) in the short term.
📊
Key Findings & Data:Materials and Methods: A total of 66 newly diagnosed primary open angle glaucoma patients were randomly distributed into 3 groups to receive latanoprost, bimatoprost or travoprost.
💡
Conclusion & Impact:It may be important to obtain pachymetry measurements at each visit in the early period of primary open angle glaucoma treatment.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: To investigate the possible impact of latanoprost, bimatoprost and travoprost on central corneal thickness (CCT) in the short term. Materials and Methods: A total of 66 newly diagnosed primary open angle glaucoma patients were randomly distributed into 3 groups to receive latanoprost, bimatoprost or travoprost. Patients with non-glaucomatous eye disease, history of trauma, contact lens use, topical drop/oinment use, lacrimal problems, or any pathology that could affect CCT were discluded from the study. All CCT measurements were recorded with ultrasonic pachymeter (Tomey, SP3000) at baseline and at 1st, 4th, and 12th weeks of treatment. Statistical analysis were conducted using SPSS 11.0 (Chicago, IL). Results: The 3 groups were similar regarding age (p=0,504) and baseline CCT (p=0.100). The mean CCT change was not significant at 1 week of treatment, but 4th and 12th week measurements showed considerable difference in all 3 groups. The mean change in CCT was 5,86 mm at 4th week and 8.39 mm at 12th week. Bimatoprost group at 12th week showed the highest percentage (52%) of CT change when pachymetric difference of >10 mm was considered. Travoprost group exhibited a significant CCT thinning even at 1st week of treatment in patients with a baseline CCT of >545 microns. Conclusion: Latanoprost, bimatoprost ve travoprost similarly caused significant CCT thinning at 4th and 12th weeks of treatment. It may be important to obtain pachymetry measurements at each visit in the early period of primary open angle glaucoma treatment.

Özet

Amaç: Latanoprost, bimatoprost ve travoprostun kısa dönemde santral kornea kalınlığı (SKK) üzerine olası etkilerini araştırmak. Gereç ve Yöntem: Kliniğimizde ilk kez primer açık açılı glokom tanısı alan toplam 66 hasta rastgele seçimle 3 ilaç grubuna dağıtıldı. Glokom haricinde göz rahatsızlığı olan, travma öyküsü bulunan, kontakt lens kullanan, gözyaşı problemi olan, herhangi bir göz damlası/pomadı kullanmakta olan veya SKK'yı etkileyecek herhangi bir patolojisi olan hastalar çalışmaya dahil edilmedi. Tüm hastaların SKK ölçümleri, tedavi öncesi ile tedavinin 1. haftası, 4. haftası ve 12. haftasında ultrasonik pakimetre kullanılarak (Tomey SP3000) kaydedildi. İstatistiksel analizler SPSS 11.0 (Chicago, IL) bilgisayar programı ile yapıldı. Bulgular: Her üç grup, yaş (p=0,504) ve tedavi öncesi SKK ortalamaları p=0.100) açısından benzerdi. Bütün gruplarda 1. hafta SKK ortalamaları tedavi öncesine göre belirgin değişmezken, 4 ve 12. haftalarda anlamlı incelme izlenmiştir. Ortalama bazal değere göre SKK incelmesi 4. haftada 5,86 μm iken, 12. haftada 8.39 μm olarak saptanmıştır. İncelmenin 10 μm üzerinde olduğu gözler değerlendirildiğinde, en çok etkilenen grubun, 12. hafta bimatoprost kullanan grup olduğu izlenmiştir. Bazal pakimetrik değeri 545 μm üzerinde olan hastalarda travoprost grubunda henüz 1. haftadan itibaren anlamlı SKK incelmesi ortaya çıkmıştır. Sonuç: Latanoprost, bimatoprost ve travoprost benzer derecede tedavinin 4. ve 12. haftalarında anlamlı SKK incelmesine yolaçmaktadır. Primer açık açılı glokom tedavisinde bu ilaçlar kullanılırken, erken dönem takiplerinde her muayenede pakimetrik değerlendirme gerekli olabilir.

🔖

Cite This Article

ÇETİNKAYA, A., ÖKTEN, Ç., AKMAN, A., AYDIN, A. Y. (2010). The impact of topical latanoprost, bimatoprost and travoprost on central corneal thickness. Glokom Katarakt, Cilt: 5 - Sayı: 2, 97–101. https://ajindex.com/articles/267692

References (14)

  1. Hoyng PF, van Beek LM.: Pharmacological therapy for glaucoma, a review. Drugs. 2000;59:411-434
  2. Parrish RK, Palmberg P, Sheu WP, the XLT study group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week randomized maskedevaluator multcenter study. Am J Ophthalmol. 2003;135:688-703
  3. Sharif NA, Kelly CR, Crider JY, et al.: Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. J Ocul Phramacol Ther. 2003;19:501-515
  4. Davies SS, Ju WK, Neufeld AH, et al.: Hydrolysis of bimatoprost (Lumigan) to its free acid by ocular tissue in vitro. J Ocul Pharmacol Ther. 2003;19:45-54
  5. Gordon MO, Beiser JA, Brandt JD, et al.: The ocular hypertension treatment study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:829-830
  6. Wolfs RC, Klaver CC, Vingerling JR, et al.: Distribution of central corneal thickness and its association with intraocular pressure: the Rotterdam Study. Am J Ophthalmol. 1997;123:767-772
  7. Yıldırım R, Oral Y, Bahçecioğlu H.: Santral kornea kalınlığı ve göz içi basıncı değerleri arasındaki ilişki. T Oft Gaz. 2000;30:319-323
  8. Doughty MJ, Zaman ML.: Human corneal thickness and its impact on intraocular pressure measures: a review and meta-analysis approach. Surv Ophthalmol. 2000;44:367-407
  9. Herndon LW, Weizer JS, Stinnett SS.: Central corneal thickness as a risk factor for advanced glaucoma damage. Arch Ophthalmol. 2004;122:17-21
  10. Shih CY, Graff Zivin JS, Trokel SL, et al.: Clinical significance of central corneal thickness in the management of glaucoma. Arch Ophthalmol. 2004;122:1270-1275
  11. Inoue K, Okugawa K, Oshika G, et al.: Influence of dorzolamide on corneal endothelium. Jpn J Ophthalmol. 2003;47:129-133
  12. Liu Y, Yanai R, Lu Y, et al.: Effects of antiglaucoma drugs on collagen gel contraction mediated by human corneal fibroblasts. J Glaucoma. 2006;15:255-259
  13. Lass JH, Eriksson GL, Osterling L, Simpson CV, for the Latanoprost Corneal Effects Study Group: Comparison of the corneal effects of latanoprost, fixed combination latanoprost-timolol, and timolol. Ophthalmology. 2001;108:264-271
  14. Viestenz A, Martus P, Schlotzer-Schrehardt U, et al.: Impact pf prostaglandin-F (2alpha)-analogues and carbonic anhydrase inhibitors on central corneal thickness: a cross-sectional study on 403 eye